Shares
Here you will find information on Sartorius preference shares (SRT3) and Sartorius ordinary shares (SRT).
Stock Chart
Stock Chart
Shares Overview
ISIN | Ordinary share: DE0007165607 | Preference share: DE0007165631 |
SE Code | Ordinary share: SRT | Preference share: SRT3 |
Capital stock | 74,880,000 euros |
Number of shares outstanding | Ordinary shares: 34,229,428 | Preference shares: 34,806,061 |
Number of shares | 74,880,000 no-par individual share certificates; thereof Ordinary shares: 37,440,000 | Preference shares: 37,440,000 |
Market Segment | Prime Standard |
Indices | DAX | TecDAX | MSCI Germany Index | CDAX | Prime All-Share-Index | Technology All Share-Index | NISAX20 | STOXX Europe 600 | DAX 50 ESG |
Market places | XETRA | Frankfurt Main | Hanover | Hamburg | Berlin | Munich | Düsseldorf | Stuttgart | Tradegate |
Designated Sponsors | Oddo Seydler Bank AG | M.M. Warburg & Co. |
First trading day | July, 10, 1990; Issue price: Ordinary share DM 710 | Preference share DM 610 |
Post IPO Activities | 04.06.1998: Capital increase by DM 11 million to DM 36 million by preference share at the issue price of DM 630 13.12.1999: Conversion of DM 50 par value shares to individual share certificate with an accounting par value of 1 euro at a ratio of 1:26 (stock split) 13.06.2016: Capital increase by use of retained earnings for carrying out a stock split at a ratio of 1:4 09.02.2024: Placement of 613,497 preference shares (the “Placement Preference Shares”) held in treasury with the exclusion of existing shareholders’ subscription rights (the “Treasury Share Placement”) at a price of 326.00 euros per share |
Paying and exchange agent for Sartorius AG shares | Commerzbank AG (Neue Börsenstraße 1, 60487 Frankfurt am Main, Germany) |
Sartorius AG is currently covered by 24 sell-side analysts. The following list shows their latest recommendations for Sartorius preference shares.
Institution | Analyst | Date | Target Price | Recommendation |
Morgan Stanley | Thibault Boutherin | 15.04.2024 | 330.00 | Equal-weight |
Jefferies | James Vane-Tempest | 11.04.2024 | 359.00 | Hold |
Citigroup | Vineet Agrawal | 10.04.2024 | 400.00 | Buy |
HSBC | Sezgi Özener | 09.04.2024 | 410.00 | Buy |
Barclays | Charles Pitman | 28.03.2024 | 350.00 | Equalweight |
JP Morgan | Richard Vosser | 28.03.2024 | 365.00 | Overweight |
Deutsche Bank | Falko Friedrichs | 27.03.2024 | 316.00 | Hold |
Bank of America | Charlie Haywood | 27.03.2024 | 390.00 | Buy |
Exane | Hugo Solvet | 27.03.2024 | 290.00 | Hold |
Stifel | Dylan Van Haaften | 25.03.2024 | 415.00 | Buy |
Kepler Chevreux | Oliver Reinberg | 19.03.2024 | 360.00 | Hold |
UBS | Matthew Weston | 13.03.2024 | 355.00 | Neutral |
Metzler | Alexander Neuberger | 19.02.2024 | 370.00 | Buy |
Warburg | Michael Heider | 19.02.2024 | 320.00 | Hold |
SRH AlsterResearch | Harald Hof | 19.02.2024 | 240.00 | Sell |
Berenberg | Odysseas Manesiotis | 16.02.2024 | 346.00 | Buy |
EQUI.TS | Thomas J. Schießle | 08.02.2024 | 349.00 | Hold |
Morningstar | Jay Lee | 30.01.2024 | 295.00 | -- |
LBBW | Volker Stoll | 29.01.2024 | 400.00 | Buy |
AlphaValue | Virendra Chauhan | 29.01.2024 | 353.00 | Buy |
KeyBanc | Paul Knight | 26.01.2024 | 415.00 | Overweight |
DZ Bank | Sven Kürten | 26.01.2024 | 230.00 | Sell |
Oddo BHF | Oliver Metzger | 26.01.2024 | 266.00 | Hold |
Redburn | Ed Ridley-Day | 10.02.2022 | 449.00 | Buy |
Disclaimer
The analysts’ estimates listed above as examples are not based on research or analyses conducted by Sartorius AG, but rather exclusively on analyses, research, reports, recommendations or ratings of third parties. References to such recommendations and ratings are provided as convenience for readers and for non-binding informational purposes only. These references do not imply that Sartorius AG adopts, endorses or confirms in any way the recommendations, options, opinions, conclusions or estimates of analysts. In particular, analysts’ estimates do not constitute any investment advice given by Sartorius AG. None of the information provided is intended as an offer or encouragement to buy Sartorius shares or other financial instruments, nor is it an offer to purchase or sell.
Sartorius AG shall not assume any liability, in particular for the selection, topicality, quality, completeness or accuracy of the analysts’ estimates shown and, if any, of analysts’ recommendations. Any liability on the part of Sartorius AG for damages or losses incurred by third parties based on the information published on this website shall be excluded.
Sartorius AG’s issued capital comprises 37,440,000 million ordinary shares and the same number of preference shares, each with a calculated par value of €1 per share. Some of both classes of share are held by the company itself. Minus these treasury shares, the number of ordinary shares outstanding is 34,229,428 and the number of preference shares outstanding is 34,806,061. A good 55 % of the ordinary shares outstanding are under the management of an executor. According to the most recent information available, the U.S. company Bio-Rad Laboratories Inc. holds around 38 % of the ordinary shares outstanding. To our knowledge, the remaining approximately 7 % are in free float.
According to the information currently available, around 28 % of the preference shares outstanding are held by Bio-Rad Laboratories Inc. and 72 % are in free float.
Ordinary shares (~34.2m shares) | Preference shares (~34.8m shares) | ||
Administered by an executor | ~55% | Free float | ~72% |
Bio-Rad Laboratories | ~38% | Bio-Rad Laboratories | ~28% |
Free float | ~7% |
Information on shareholdings and shares in free float pursuant to the disclosure requirements of Sections 33 et seq. of the German Securities Trading Act (WpHG) and the shareholders’ own disclosures. These reporting obligations and own disclosures refer only to voting shares and not to non-voting preference shares. For this reason, the shareholder structure disclosed for Sartorius preference shares does not contain any detailed information beyond the company’s treasury shares.